Tandem Diabetes Care, Inc. (NASDAQ:TNDM) shares saw an uptick in trading volume on Friday . 2,155,740 shares traded hands during mid-day trading, an increase of 61% from the previous session’s volume of 1,339,390 shares.The stock last traded at $0.82 and had previously closed at $0.72.

Separately, Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research note on Thursday, September 28th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $4.46.

The company has a 50-day moving average price of $0.68 and a 200-day moving average price of $0.82. The stock’s market capitalization is $41.19 million.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.04. Tandem Diabetes Care had a negative net margin of 110.70% and a negative return on equity of 1,177.11%. The company had revenue of $21.30 million during the quarter, compared to the consensus estimate of $21.74 million. During the same quarter in the prior year, the firm earned ($0.60) earnings per share. The firm’s revenue was down 7.4% compared to the same quarter last year. On average, equities research analysts forecast that Tandem Diabetes Care, Inc. will post ($1.79) earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after purchasing an additional 32,991 shares during the last quarter. Bank of America Corp DE boosted its holdings in Tandem Diabetes Care by 88.6% during the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after purchasing an additional 404,452 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Tandem Diabetes Care by 93.3% during the second quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock worth $465,000 after purchasing an additional 280,551 shares during the last quarter. Paulson & CO. Inc. acquired a new position in Tandem Diabetes Care during the first quarter worth $600,000. Finally, Keybank National Association OH boosted its holdings in Tandem Diabetes Care by 32.7% during the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after purchasing an additional 72,177 shares during the last quarter. Institutional investors and hedge funds own 36.64% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Tandem Diabetes Care, Inc. (TNDM) Sees Large Volume Increase” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/06/tandem-diabetes-care-inc-tndm-sees-large-volume-increase.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Receive News & Stock Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related stocks with our FREE daily email newsletter.